1. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: A randomized, placebo-controlled cross-over study 
Tannetje I. Bron, Denise Bijlenga, A. Marije Boonstra, Minda Breuk, Willem F.H. Pardoen, Aartjan T.F. Beekman, J.J. Sandra Kooij 
European Neuropsychopharmacology 
Volume 24, Issue 4, Pages (April 2014)
DOI: /j.euroneuro
Copyright © 2014 Elsevier B.V. and ECNP Terms and Conditions

2. Figure 1
Flowchart of the 6-weeks procedure and randomizations of our double-blind, placebo-controlled cross-over study, with every subject receiving both treatments. Note: n=group size; SCID=Structured Clinical Interview for DSM disorders; CPTs=continuous performance tests.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2014 Elsevier B.V. and ECNP Terms and Conditions

3. Figure 2
Mean delta scores on C-CPT and TOVA HRT, RTV and OE for patients having no, few or multiple EF deficits at baseline. Note: Baseline is used as the reference category, the lines illustrate the mean delta scores for baseline vs. placebo, and baseline vs. OROS-mph.
* Significant difference between groups of heterogeneity at an α-level of .017, following a Bonferroni correction for multiple comparisons.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2014 Elsevier B.V. and ECNP Terms and Conditions

4. Figure 3
Increases or decreases of self-reported ADHD symptoms as measured with the ADHD Rating Scale Total score after placebo or 72mg OROS-mph medication, as compared to baseline. Note: Baseline is used as the reference category. OROS-mph=osmotic-release methylphenidate.
* Significant differences between baseline and OROS-mph at an α-level of .05 or smaller.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2014 Elsevier B.V. and ECNP Terms and Conditions